Kairos Pharma, Ltd. (KAPA)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	51.06M
Revenue (ttm)	n/a
Net Income (ttm)	-812,000
Shares Out	12.77M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About KAPA

Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 3
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: KAPA